Inhaled vs. oral alprazolam: Subjective, behavioral and cognitive effects, and modestly increased abuse potential

Psychopharmacology

Volumn 232, Issue 5, 2015, Pages 871-883

  Reissig, Chad J ^a   Harrison, Joseph A ^a   Carter, Lawrence P ^b   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Abuse potential; Alprazolam; Drug abusers; Humans; Inhalation; Liking; Oral; Performance; Staccato

Indexed keywords

ALPRAZOLAM; PLACEBO;

ABUSE POTENTIAL; ARTICLE; BEHAVIOR ASSESSMENT; COGNITION; DOSE RESPONSE; DRUG ABUSE; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL PERFORMANCE; NORMAL HUMAN; RISK ASSESSMENT; ADOLESCENT; ADULT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRE; RECALL; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALPRAZOLAM; COGNITION; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; SUBSTANCE-RELATED DISORDERS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84922793377     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3721-0     Document Type: Article

References (36)

1. Abreu ME, Bigelow GE, Fleisher L, Walsh SL (2001) Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacol (Berl) 154:76-84
2. Alexza Pharmaceuticals (2014a) Investigator's brochure for study AZ-002
3. Alexza Pharmaceuticals (2014b) Product Website frequently asked questions (FAQ). Available online at: http://www.alexza.com/products/faq. Accessed 30 May 2014
4. Alexza Pharmaceuticals (2014c) Product Website frequently asked questions (FAQ). Available online at: http://www.alexza.com/products/faq. Accessed on June 26, 2014
5. Avram MJ, Henthorn TK, Spyker DA, Krejcie TC, Lloyd PM, Cassella JV, Rabinowitz JD (2007) Recirculatory pharmacokinetic model of the uptake, distribution, and bioavailability of prochlorperazine administered as a thermally generated aerosol in a single breath to dogs. Drug Metab Dispos 35:262-267
6. Avram MJ, Spyker DA, Henthorn TK, Cassella JV (2009) The pharmacokinetics and bioavailability of prochlorperazine delivered as a thermally generated aerosol in a single breath to volunteers. Clin Pharmacol Ther 85:71-77
7. Avram MJ, Spyker DA, Kehne JH, Cassella JV (2013) The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers. J Clin Pharmacol 53(2):140-150
8. Balster RL, Schuster CR (1973) Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 20:119-129
9. Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31:2537-2551
10. Carter LP, Griffiths RR, Mintzer MZ (2009) Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacol (Berl) 206:141-154
11. de Wit H, Bodker B, Ambre J (1992) Rate of increase of plasma drug level influences subjective response in humans. Psychopharmacol (Berl) 107:352-358
12. de Wit H, Dudish S, Ambre J (1993) Subjective and behavioral effects of diazepam depend on its rate of onset. Psychopharmacol (Berl) 112:324-330
13. Evans SM, Funderburk FR, Griffiths RR (1990) Zolpidem and triazolam in humans: behavioral and subjective effects and abuse liability. J Pharmacol Exp Ther 255:1246-1255
14. Fischman MW, Schuster CR (1984) Injection duration of cocaine in humans. Fed Poc 43:570
15. Gorelick DA (1998) The rate hypothesis and agonist substitution approaches to cocaine abuse treatment. Adv Pharmacol 42:995-997
16. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 24:453-471
17. Griffiths RR, McLeod DR, Bigelow GE, Liebson IA, Roache JD (1984) Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacol (Berl) 84:147-154
18. Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV (1985) Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 9:133-151
19. Kato S, Wakasa Y, Yanagita T (1987) Relationship between minimum reinforcing doses and injection speed in cocaine and pentobarbital self-administration in crab-eating monkeys. Pharmacol Biochem Behav 28:407-410
20. Macleod DB, Habib AS, Ikeda K, Spyker DA, Cassella JV, Ho KY, Gan TJ (2012) Inhaled fentanyl aerosol in healthy volunteers: pharmacokinetics and pharmacodynamics. Anesth Analg 115:1071-1077
21. Marsch LA, Bickel WK, Badger GJ, Rathmell JP, Swedberg MD, Jonzon B, Norsten-Hoog C (2001) Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther 299:1056-1065
22. McLeod DR, Griffiths RR, Bigelow GE, Yingling J (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods & Instrum 14:463-466
23. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR (1995a) Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 57:356-365
24. Mumford GK, Rush CR, Griffiths RR (1995b) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272:570-580
25. Nelson RA, Boyd SJ, Ziegelstein RC, Herning R, Cadet JL, Henningfield JE, Schuster CR, Contoreggi C, Gorelick DA (2006) Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 82:19-24
26. Neubauer DN (2010) ZolpiMist: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US. Nat Sci Sleep 2:79-84
27. Oldendorf WH (1992) Some relationships between addiction and drug delivery to the brain. NIDA Res Monogr 120:13-25
28. Rabinowitz JD, Wensley M, Lloyd P, Myers D, Shen W, Lu A, Hodges C, Hale R, Mufson D, Zaffaroni A (2004) Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther 309:769-775
29. Rabinowitz JD, Lloyd PM, Munzar P, Myers DJ, Cross S, Damani R, Quintana R, Spyker DA, Soni P, Cassella JV (2006) Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci 95:2438-2451
30. Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacol (Berl) 223:1-15
31. Roset PN, Farre M, de la Torre R, Mas M, Menoyo E, Hernandez C, Cami J (2001) Modulation of rate of onset and intensity of drug effects reduces abuse potential in healthy males. Drug Alcohol Depend 64:285-298
32. Rush CR, Frey JM, Griffiths RR (1999) Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacol (Berl) 145:39-51
33. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacol (Berl) 84:452-456
34. Spyker DA, Munzar P, Cassella JV (2010) Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 50:169-179
35. Wakasa Y, Takada K, Yanagita T (1995) Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys. Nihon Shinkei Seishin Yakurigaku Zasshi 15:53-59
36. Woolverton WL, Wang Z (2004) Relationship between injection duration, transporter occupancy and reinforcing strength of cocaine. Eur J Pharmacol 486:251-257